Your Messages Inbox
Your Article Summary
See Latest ArticlesFebruary 2009 FDA Approves ULORICA (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
Takeda Pharmaceuticals North America, 02/16/09
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral medication is the first new treatment option in more than 40 years for the more than five million patients who have hyperuricemia associated with gout. ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the U.S. market.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/10/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Article Search
Sponsor